Abstain from your annual health check-up and your odds of being diagnosed with cancer at an advanced stage rise to about 1.78 times those of people who attend. That is an adjusted odds ratio of 1.78, 95% confidence interval 1.29 to 2.44, from a retrospective cohort study in Environmental Health and Preventive Medicine: 72,171 National Health Insurance enrollees in Tottori Prefecture, Japan, aged 40 to 74, tracked from 2014 to 2017 against the cancer registry. “Advanced” there means the cancer had reached regional or distant spread by the time it was found, rather than sitting localized where it began. The same abstainers also carried higher odds, 1.21, of a cancer diagnosis at all.
Flag the proxy before going further, because it is load-bearing. This is a Japanese cohort. No equivalent study measures the advanced-stage odds for Western retirees in Southeast Asia; that figure does not exist. What transfers is the mechanism and the direction of its magnitude, not a measured expat rate. Hold that caveat through everything below.
The number on its own is a public-health finding about attendance. The reason it belongs on this site is what relocation does to attendance, and it does something specific. The move does not make a careful screener careless. It removes the machinery that was screening them.
Screening is a recall system, not a test you book
Treat this as the correction the rest of the genre will not make, because it does not look like a relocation problem at all.
At home, in a country with an organized programme, you are not really the one doing the screening. A system is. The UK NHS Bowel Cancer Screening Programme mails a free faecal-immunochemical-test kit every two years to everyone aged 50 to 74 who is registered with a GP, posted to the address the GP holds. Breast and cervical programmes work the same way: a register, a clock, a letter that arrives whether or not you remembered. You complete the test because something outside you started the process and put a deadline on it. The initiative is institutional. Your only job is not to ignore the envelope.
That is what an organized screening programme is: a call-recall system keyed to a register and an address. It is also, for most people, invisible. You do not experience it as a service. You experience it as an occasional bit of admin that turns up unbidden. And because it was free and involuntary and you never had to seek it out, you stop counting it as one of the things holding your health together. It is the medical version of the scaffolding that holds an expat life up until the move removes it — supports you only notice in their absence.
Now move abroad. The register no longer holds a usable address. The clock keeps running on a programme that can no longer reach you. The letter goes to a house you sold. The abstention the Japanese study measured as a behaviour becomes, for the relocated retiree, a structural fact: not a choice to skip the screen, but the quiet removal of the thing that would have prompted it.
Deregistration can sever the system entirely
There is a sharper version of this for the expat who tidies up properly before leaving, and it cuts the wrong way.
The conscientious mover deregisters. They tell the GP they have left, close the council-tax account, update HMRC, do the responsible thing and stop pretending to live somewhere they do not. Eligibility for the home screening programme is keyed to exactly those registrations — GP enrollment and a held home address are the stated preconditions for receiving the kit. Deregister, and you do not just stop receiving the next kit. You can fall out of eligibility for the programme altogether, with no automatic route back in while you are non-resident. The person who left things in a mess might still get the envelope. The person who did it correctly gets nothing.
This is the same structural trap that runs through the rest of the aging-abroad ledger. What Medicare and the NHS will not cover in Southeast Asia is the larger case of it: the home safety net is residence-based, and residence is the thing you gave up. Screening is one more entitlement that was never withdrawn from you. It simply stopped being able to find you.
The destination has no recall machinery either
A reasonable objection: surely you just get screened where you live now. The hospitals in Bangkok and Manila are real, some of them excellent, and a colonoscopy or a mammogram is available and often inexpensive. True. It does not solve the problem, because the problem was never availability. It was initiation.
Across Thailand and the Philippines, organized population-based screening with systematic call-recall is largely absent or incompletely implemented; screening is predominantly opportunistic and patient-initiated. The Philippines is classified opportunistic across breast, cervical, colorectal and prostate cancer. Thailand has built some organized cervical and colorectal design but has no national breast-screening programme, and its colorectal screening is delivered opportunistically through urban hospitals rather than as a population call-recall. Opportunistic means the screen happens if, and only if, the patient seeks it out. No kit arrives. No letter is sent. No register holds your name on a two-year clock.
So the relocated expat lands in the gap between two systems. The home programme can no longer reach them; the destination has no programme reaching for anyone. Both ends of the move default to the same arrangement: screening occurs only on the individual’s own initiative, with nothing external to prompt it. That is the precise condition the abstention odds ratio describes, installed not by carelessness but by geography.
The stage-shift stack
Put the pieces in order and they compound. This is the synthesis — the model the brochure and the insurer blog will not assemble, because every layer in it is a thing that does not photograph. Each row carries the source it rests on.
| Layer | Rests on | What it does |
|---|---|---|
| Baseline abstention penalty | Rests on EHPM 2022 (Japan) | What it does Skipping routine check-ups carries OR 1.78 (1.29–2.44) for an advanced-stage diagnosis. Abstention is already the majority behaviour — compliance under 50%. |
| Move removes organized recall | Rests on NHS England | What it does The home GP register and the mailed kit that initiated the screen on a two-year clock no longer have a usable address. The prompt stops arriving. |
| Deregistration severs access | Rests on NHS England | What it does Eligibility is keyed to GP enrollment and a held home address. Deregister cleanly and you can fall out of the national programme entirely, with no automatic way back in. |
| Destination is opportunistic | Rests on BMC HSR 2023 | What it does Thailand and the Philippines screen patient-initiated, no call-recall. The test exists; nothing tells you it is time. You become the structural never-attender. |
| Output: stage at diagnosis | Rests on SEER; CRUK | What it does The cancer is found later. For colorectal, 5-year survival is 91.3% caught localized and 16.9% once distant — the gap the whole stack is paid in. |
Source: Kuwabara et al EHPM 2022; NHS England bowel screening; BMC Health Services Research 2023; NCI SEER; Cancer Research UK (c1, c4–c7) · checked 2026-06-06
The magnitudes worth ranking sit at the two ends of that stack: how much abstention shifts the odds, and where the patient sits on the engagement scale once they have moved.
Source: Kuwabara et al EHPM 2022 (Japan); Flanders breast-screening cohort, n=38,005 (Belgium) · checked 2026-06-06
The Japanese 1.78 is an average across everyone who skipped a check-up, many of whom would screen again next year. It understates the expat case, because the expat is not an occasional skipper. Read the Belgian numbers instead. A population study of 38,005 women in Flanders graded the penalty by engagement: irregular attenders had OR 1.17 for an advanced-stage breast cancer diagnosis, women who attended only once had 2.18, and never-attenders had 5.95, nearly six times the odds of the women the system kept reaching. That is a Western cohort, and it is the relevant tail. The relocated retiree, with no kit arriving and no programme reaching them, is the never-attender by construction. Neither figure is an expat measurement, and neither is a forecast for any individual. Both say the same thing about where the curve runs.
Stage is the variable that decides survival
The reason any of this matters reduces to a single fact about cancer: stage at diagnosis is the strongest lever on whether the patient lives.
The same cancer, found at two different stages. Screening exists to keep the diagnosis on the left side of that gap; abstention lets it cross to the right.
Those are SEER figures for colorectal cancer, 5-year relative survival by stage at diagnosis: 91.3% when localized, 75.2% regional, 16.9% once it has reached distant sites. Cancer Research UK reports the identical cliff for bowel cancer in England: around 90% surviving five years at stage 1, falling to roughly 10% at stage 4. Two independent registries, the same shape: a survivable disease at one end and a usually fatal one at the other, and the only difference between them is when it was caught.
That is the whole point of a screening programme. It does not treat cancer. It moves the moment of diagnosis up that survival curve, from the right-hand side where the cancer is felt as a symptom to the left-hand side where it is found as a number on a stool test before it has announced itself. The abstention odds ratio and the survival-by-stage cliff are the same finding stated twice. Skipping the screen raises the odds the cancer is found late; found late, it sits on the 16.9% end of the curve instead of the 91.3% end.
So trace the move all the way through. Relocation removes the recall that kept the reader attending. Non-attendance raises the odds of an advanced-stage diagnosis. Advanced stage, for the common cancers, is the difference between a disease most people survive and one most people do not. The chain is sourced at every link and it terminates somewhere specific: not in a higher abstract risk, but in the stage printed on a pathology report years from now, and in the survival percentage attached to it.
What would have to be true to break the stack
The register is description, so state the exits plainly. They exist, and none of them is the default.
The stack breaks if the reader replaces the recall they lost with one they build by hand — a fixed personal schedule for the age-appropriate screens, colorectal and breast and cervical and whatever else applies, booked and paid in the destination on the same clock the home programme used, with no envelope to remind them. That demands the person supply, from memory and discipline, exactly the prompting the system used to supply for free. It is doable. It is also the precise thing the data says most people do not do once the prompt is gone, which is why opportunistic uptake runs below call-recall uptake everywhere it has been compared.
It breaks if home eligibility is preserved rather than severed — if the reader does not deregister in a way that closes the programme to them, and retains a route back into the kit. Whether that is possible depends on the rules of the specific home system and is the kind of thing this site will not tell you to do; verify it with the programme itself, because the wrong move here is irreversible in a way the brochure never mentions.
And it breaks if the reader simply accepts the figure for what it is and treats screening as the one piece of home admin that does not lapse on the move. That is the cheapest of the exits and the most commonly skipped, because nothing about a new life abroad makes it feel urgent. The kit used to make it feel urgent. The kit is not coming.
Strip those out and what remains is the arrangement the abstention study measured, installed by geography rather than by choice: a person no programme is screening, in a place that screens no one it is not asked to, carrying odds the data already attached to that position. The cancer, if it comes, does not care that the lapse was structural rather than careless. It is staged the same either way.